Related Experiment Video

Updated: May 25, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Met interacts with EGFR and Ron in canine osteosarcoma

J K McCleese1, M D Bear, S K Kulp

  • 1Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.

Veterinary and Comparative Oncology
|January 13, 2012
PubMed

Insights

Met, EGFR, and Ron receptor tyrosine kinases interact in canine osteosarcoma, suggesting they are potential therapeutic targets for this cancer.

Area of Science:

  • Veterinary Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Met receptor tyrosine kinase (RTK) is over-expressed in canine osteosarcoma (OSA).
  • In human cancers, Met, epidermal growth factor receptor (EGFR), and Ron RTKs are co-expressed, leading to therapeutic resistance.
  • Understanding these interactions in canine OSA is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the expression and interaction of Met, EGFR, and Ron in canine osteosarcoma.
  • To explore the functional consequences of receptor cross-talk in OSA cells.
  • To evaluate the efficacy of combined targeted inhibition of these receptors.

Main Methods:

  • Immunohistochemistry and Western blotting to assess protein expression and phosphorylation.
  • Cell culture and stimulation with growth factors (TGFα, HGF).
  • Pharmacological inhibition using gefitinib (EGFR inhibitor) and crizotinib (Met inhibitor).

Main Results:

  • EGFR and Ron are expressed and phosphorylated in canine OSA tissues and cell lines.
  • Met co-associates with EGFR and Ron in OSA cells, indicating potential heterodimerization.
  • Growth factor stimulation leads to amplified ERK1/2 and STAT3 phosphorylation, with Met activation by TGFα, confirming receptor cross-talk.
  • Combined gefitinib and crizotinib treatment additively inhibited OSA cell proliferation.

Conclusions:

  • Met, EGFR, and Ron interact and crosstalk in canine OSA cells.
  • These receptor tyrosine kinases represent promising therapeutic targets for canine osteosarcoma.
  • Combined inhibition strategies may offer a viable approach for treating canine OSA.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...